Conference Reports for NATAP
Back
 
11th Workshop on Adverse Drug Reactions and Co-morbidities in HIV, Philadelphia, USA, October 26-28 2009
Omega-3 fatty acids supplementation may improve inflammation and endothelial activation in HIV-infected adults on stable antiretroviral therapy
- (05/24/10)
 
Vitamin D and Efavirenz
- (05/24/10)
 
Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D
- (05/24/10)
 
Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV - Workshop report
- (01/28/10)
 
EACS:
Feedback Reports (clinical, translational) from the 11th International Workshop on Adverse Drug reactions and Co-morbidities in HIV reported at EACS 2009 Cologne
- (11/20/09)
 
Framingham Risk and Lipoprotein Changes after 24 Weeks of Treatment with Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral-Naive HIV-1 Infected Subjects
- (12/03/09)
 
Both once-daily saquinavir / ritonavir and atazanavir / ritonavir, when combined with tenofovir / emtricitabine conserve adipose tissue, only modestly affect lipids and exhibit similar mild reductions in glomerular filtration rate over 48 weeks: the BASIC trial
- (10/28/09)
 
Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-naïve HIV-1 infected patients: ARTEN Study Week 48 results
- (10/28/09)
 
Neuropsychiatric adverse events in the MONET trial: darunavir/ritonavir with and without nucleoside analogues for patients with HIV RNA <50 copies/mL at screening
- (10/27/09)
 
Correlation between laboratory parameters and use or discontinuation of nucleoside analogues in the MONET trial
- (10/27/09)
 
48 week changes in Quality of Life and adherence in the MONET trial: darunavir/ritonavir with and without nucleoside analogues for patients with HIV RNA <50 at screening
- (10/27/09)